MicroBiome Therapeutics has a lead product focused on diabetes treatment, while UK-based 4D Pharma is targeting irritable bowel syndrome and paediatric Crohn's Disease. These treatments are given ...
Close the Clinical Gap, Discover the Next Generation of Microbiome-based Therapeutics, and Establish New Partnerships to Accelerate Your Research We will continue to unite forward-thinking ...
Hosted on MSN4d
Human microbiome market to reach $4.85b by 2031APAC is expected to grow the fastest in the coming years. The global human microbiome market is projected to grow from $1.07b ...
The Microbiome Therapeutics Market sector is poised for substantial growth, with a projected rise in market size by USD 974 million and a Compound Annual Growth Rate (CAGR) of 27.8% expected by the ...
A study revealed highly specific gut microbiome signatures for NAFLD, using machine learning to differentiate the disease ...
The human microbiome market share is expected to reach US$ 4.85 billion by 2031, driven by increased investments in research, ...
The NiMe Diet—rooted in non-industrialized eating patterns—outpaces the Paleo diet with science-backed health benefits, ...
About Siolta Therapeutics Siolta Therapeutics ... aimed at preventing and treating diseases impacted by the human microbiome with a focus on the maternal-infant axis. Learn more at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback